- Home
- ACAD vs CRGY Comparison
ACAD vs CRGY Comparison
Compare ACAD & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CRGY
- Stock Information
- Founded
- ACAD 1993
- CRGY 1986
- Country
- ACAD United States
- CRGY United States
- Employees
- ACAD N/A
- CRGY N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CRGY Oil & Gas Production
- Sector
- ACAD Health Care
- CRGY Energy
- Exchange
- ACAD Nasdaq
- CRGY Nasdaq
- Market Cap
- ACAD 2.5B
- CRGY 2.2B
- IPO Year
- ACAD 2004
- CRGY N/A
- Fundamental
- Price
- ACAD $22.71
- CRGY $9.48
- Analyst Decision
- ACAD Buy
- CRGY Buy
- Analyst Count
- ACAD 16
- CRGY 12
- Target Price
- ACAD $27.00
- CRGY $16.40
- AVG Volume (30 Days)
- ACAD 1.6M
- CRGY 3.2M
- Earning Date
- ACAD 08-05-2025
- CRGY 08-04-2025
- Dividend Yield
- ACAD N/A
- CRGY 5.07%
- EPS Growth
- ACAD N/A
- CRGY N/A
- EPS
- ACAD 1.37
- CRGY N/A
- Revenue
- ACAD $996,283,000.00
- CRGY $3,223,618,000.00
- Revenue This Year
- ACAD $13.39
- CRGY $25.86
- Revenue Next Year
- ACAD $10.59
- CRGY N/A
- P/E Ratio
- ACAD $16.65
- CRGY N/A
- Revenue Growth
- ACAD 22.42
- CRGY 31.58
- 52 Week Low
- ACAD $13.40
- CRGY $6.83
- 52 Week High
- ACAD $25.23
- CRGY $16.94
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- CRGY 57.21
- Support Level
- ACAD $21.35
- CRGY $9.41
- Resistance Level
- ACAD $22.69
- CRGY $9.88
- Average True Range (ATR)
- ACAD 0.76
- CRGY 0.38
- MACD
- ACAD -0.13
- CRGY 0.07
- Stochastic Oscillator
- ACAD 70.76
- CRGY 67.59
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.